Spitzoid melanoma

Summary

Spitzoid melanoma (MONDO:0850101) is a cancer and 2 clinical trials. Top therapeutic interventions include tovorafenib. A subtype of cutaneous melanoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	spitzoid melanoma
Mondo ID	MONDO:0850101
DOID	DOID:0070326
NCIT	C165497
UMLS	C3495721
MedGen	1713307
Is cancer (heuristic)	yes

Disease family

This is a subtype of cutaneous melanoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › integumentary system cancer › skin cancer › cutaneous melanoma › spitzoid melanoma

Related subtypes (9): eyelid melanoma, balloon cell malignant melanoma, nodular malignant melanoma, acral lentiginous melanoma, amelanotic skin melanoma, superficial spreading melanoma, lentigo maligna melanoma, desmoplastic melanoma, melanoma in congenital melanocytic nevus

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04985604	PHASE2	TERMINATED	Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
NCT06680323	Not specified	RECRUITING	Identification of Risk Factors, Exposomics and Genetic Susceptibility of Melanoma in Children, Adolescents and Young Adults

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TOVORAFENIB	4	1